德康医疗（DXCM）今日夜盘股价大涨8.18%，引发市场广泛关注。
消息面上，公司盘后公布的季度财报表现亮眼，成为推动股价上涨的核心催化剂。得益于连续血糖监测仪（CGM）的强劲需求，德康医疗第二季度营收达到13.1亿美元，同比增长约13%，高于分析师预期的12.9亿美元；调整后每股收益为0.70美元，大幅超越市场预期的0.61美元。同时，公司上调了全年营收指引，预计全年营收将在51.8亿美元至52.5亿美元之间，此前区间下限为51.6亿美元，进一步增强了市场信心。
此外，公司G7系统近期获得加拿大卫生部授权，德国市场推出Flex系统拓展2型糖尿病覆盖，叠加产品持续创新与保险覆盖范围扩大等多重利好，投资者对德康医疗的长期增长前景保持乐观，多家投行维持买入评级，平均目标价约86美元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.